(Q44904792)

English

Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Ahmed El-Sohemy

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

author name string

Robin E Duncan

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Michael C Archer

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

language of work or name

0 references

publication date

20 May 2004

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Journal of Biological Chemistry

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

279

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

33079-33084

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Regulation of the mevalonate pathway

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Essential role for mevalonate synthesis in DNA replication

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

p21ras is modified by a farnesyl isoprenoid

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Inhibition of N-methyl-N-nitrosourea- and 7,12-dimethylbenz[a] anthracene-induced rat mammary tumorigenesis by dietary cholesterol is independent of Ha-Ras mutations.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Cholestyramine promotes 7,12-dimethylbenzanthracene induced mammary cancer in Wistar rats

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Treatment with lovastatin, cholestyramine or niacin alters K-ras membrane association in mouse lung in a strain-dependent manner: results in females

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Statin use and the risk of breast and prostate cancer

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Systematic variation in gene expression patterns in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Further evidence to support the melanocytic origin of MDA-MB-435

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Inhibition of cdk2 activating phosphorylation by mevastatin

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Distinct roles for cyclins E and A during DNA replication complex assembly and activation

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Principles of CDK regulation

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Cancer cell cycles

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Statins can inhibit proliferation of human breast cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400732200

21 January 2018

Identifiers

10.1074/JBC.M400732200

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44904792&oldid=2056291907"